<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<rss version="2.0">
<channel>
<title>Abbott MediaRoom (Product)</title>
<link>https://abbott.mediaroom.com/</link>
<description></description>
<item>
<title>New Abbott Panbio™ COVID-19/Flu A&amp;B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season</title>
<link>https://abbott.mediaroom.com/2026-11-10-New-Abbott-Panbio-TM-COVID-19-Flu-A-B-Self-Test-Helps-Canadian-Families-Make-Informed-Decisions-During-Respiratory-Illness-Season</link>
<description></description>
<pubDate>Tue, 10 Nov 2026 13:44:00 -0500</pubDate>
<guid>https://abbott.mediaroom.com/2026-11-10-New-Abbott-Panbio-TM-COVID-19-Flu-A-B-Self-Test-Helps-Canadian-Families-Make-Informed-Decisions-During-Respiratory-Illness-Season</guid>
</item>
<item>
<title>Abbott Receives FDA Approval and CE Mark for Implantable Cardioverter-Defibrillator Lead Designed to Work with the Heart&apos;s Natural Electrical System</title>
<link>https://abbott.mediaroom.com/press-releases?item=124791</link>
<description></description>
<pubDate>Tue, 10 Nov 2026 09:00:00 -0500</pubDate>
<guid>https://abbott.mediaroom.com/press-releases?item=124791</guid>
</item>
<item>
<title>Late-breaking one-year data show Abbott&apos;s next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke</title>
<link>https://abbott.mediaroom.com/2026-11-02-Late-breaking-one-year-data-show-Abbotts-next-generation-Amulet-360-TM-device-continues-to-demonstrate-high-rates-of-left-atrial-appendage-closure-and-low-incidence-of-stroke</link>
<description></description>
<pubDate>Mon, 02 Nov 2026 09:00:00 -0500</pubDate>
<guid>https://abbott.mediaroom.com/2026-11-02-Late-breaking-one-year-data-show-Abbotts-next-generation-Amulet-360-TM-device-continues-to-demonstrate-high-rates-of-left-atrial-appendage-closure-and-low-incidence-of-stroke</guid>
<enclosure url="https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=thumbnail" type="image/jpeg" />
</item>
<item>
<title>Abbott&apos;s TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System</title>
<link>https://abbott.mediaroom.com/2026-11-01-Abbotts-TECTONIC-clinical-trial-demonstrates-strong-30-day-outcomes-and-high-procedural-success-for-its-investigational-SonicForce-TM-Coronary-Intravascular-Lithotripsy-System</link>
<description></description>
<pubDate>Sun, 01 Nov 2026 15:45:00 -0500</pubDate>
<guid>https://abbott.mediaroom.com/2026-11-01-Abbotts-TECTONIC-clinical-trial-demonstrates-strong-30-day-outcomes-and-high-procedural-success-for-its-investigational-SonicForce-TM-Coronary-Intravascular-Lithotripsy-System</guid>
<enclosure url="https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=thumbnail" type="image/jpeg" />
</item>
<item>
<title>Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease</title>
<link>https://abbott.mediaroom.com/2026-10-29-Abbott-initiates-pivotal-trial-for-Cephea-TM-device,-an-innovative-treatment-for-mitral-heart-valve-disease</link>
<description></description>
<pubDate>Thu, 29 Oct 2026 09:00:00 -0400</pubDate>
<guid>https://abbott.mediaroom.com/2026-10-29-Abbott-initiates-pivotal-trial-for-Cephea-TM-device,-an-innovative-treatment-for-mitral-heart-valve-disease</guid>
<enclosure url="https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=thumbnail" type="image/jpeg" />
</item>
</channel>
</rss>
